Compare Illumina, Inc. (ILMN) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Texas Instruments Incorporated — how do they compare? Illumina, Inc. trades at $189.78 (market cap $27.94B), while Texas Instruments Incorporated trades at $293.69 (market cap $258.53B). The key difference: Texas Instruments Incorporated is far larger — about 9.3× Illumina, Inc.'s market cap, and Texas Instruments Incorporated pays a 2% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TXN | |
|---|---|---|
Market Cap | $27.94B | $258.53B |
Sector | Health | Technology |
52-Week High | $194.33 | $332.35 |
52-Week Low | $91.00 | $153.33 |
Enterprise Value | $29.33B | $267.48B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Texas Instruments (TXN) trades at $284.02, down 2.47% over 24 hours, with technical signals leaning bearish. The company reported mixed recent earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue and net income have shown volatility, with 2025 figures at $17.68B and $5.00B respectively. Analysts maintain a consensus Buy rating with a $313.05 price target, indicating potential upside. Recent CFO transition news and AI-driven demand in data centers are key developments.
Outlook remains cautiously optimistic given strong profitability margins and analyst support, but risks include elevated valuation multiples and competitive pressures in the semiconductor sector. The stock's current price near support at $281 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
